We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
Cap. Flow
+$1.13B
Cap. Flow %
11.96%
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$51.9M
2
MRK icon
Merck
MRK
+$50.9M
3
DHR icon
Danaher
DHR
+$45.3M
4
TMO icon
Thermo Fisher Scientific
TMO
+$37.8M
5
JD icon
JD.com
JD
+$37.7M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$103M
2
BABA icon
Alibaba
BABA
+$98.6M
3
CRM icon
Salesforce
CRM
+$62.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$59.4M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 34.61%
2 Technology 20.94%
3 Consumer Discretionary 8.9%
4 Financials 8.59%
5 Communication Services 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSM icon
26
TSMC
TSM
$2.09T
$63.5M 0.67%
1,117,934
-335,203
-23% -$17.7M
ALXN
27
DELISTED
Alexion Pharmaceuticals
ALXN
$63.3M 0.67%
564,099
-11,695
-2% -$1.24M
JPM icon
28
JPMorgan Chase
JPM
$939B
$60.8M 0.64%
646,132
+83,962
+15% +$7.97M
CSCO icon
29
Cisco
CSCO
$450B
$57.8M 0.61%
1,143,158
-413,605
-27% -$18.1M
NVDA icon
30
NVIDIA
NVDA
$5.01T
$57.7M 0.61%
5,917,200
-444,320
-7% -$3.59M
JNJ icon
31
Johnson & Johnson
JNJ
$635B
$57.7M 0.61%
410,381
+14,735
+4% +$2.15M
UNH icon
32
UnitedHealth
UNH
$382B
$57.6M 0.61%
195,341
-26,316
-12% -$7.54M
INTC icon
33
Intel
INTC
$466B
$54.6M 0.58%
912,138
-64,060
-7% -$3.83M
NKE icon
34
Nike
NKE
$61.9B
$54M 0.57%
550,299
+136,220
+33% +$12.6M
PEP icon
35
PepsiCo
PEP
$186B
$52.4M 0.55%
396,306
-65,028
-14% -$8.57M
ADBE icon
36
Adobe
ADBE
$89.5B
$51.7M 0.55%
118,814
-23,596
-17% -$8.74M
WM icon
37
Waste Management
WM
$95.9B
$50.2M 0.53%
474,335
+84,381
+22% +$8.52M
AVGO icon
38
Broadcom
AVGO
$1.82T
$50M 0.53%
1,583,210
+62,720
+4% +$1.76M
LLY icon
39
Eli Lilly
LLY
$1.07T
$47.6M 0.5%
290,023
-8,802
-3% -$1.35M
BIO icon
40
Bio-Rad Laboratories Class A
BIO
$8.42B
$46.6M 0.49%
103,145
+23,644
+30% +$10.4M
BMRN icon
41
BioMarin Pharmaceuticals
BMRN
$11.5B
$45.6M 0.48%
369,640
+47,225
+15% +$4.69M
JD icon
42
JD.com
JD
$40.8B
$44.8M 0.47%
+744,410
New +$37.7M
SPGI icon
43
S&P Global
SPGI
$126B
$44M 0.46%
133,670
+30,892
+30% +$9.29M
ADI icon
44
Analog Devices
ADI
$181B
$43.9M 0.46%
358,192
+69,550
+24% +$7.64M
ABT icon
45
Abbott
ABT
$180B
$43.5M 0.46%
476,059
-180,303
-27% -$16.3M
MA icon
46
Mastercard
MA
$477B
$42.9M 0.45%
145,132
+9,793
+7% +$2.76M
ROK icon
47
Rockwell Automation
ROK
$51.4B
$42M 0.44%
197,030
-17,723
-8% -$3.43M
SPLK
48
DELISTED
Splunk Inc
SPLK
$41.9M 0.44%
210,744
+70,079
+50% +$11.1M
IMMU
49
DELISTED
Immunomedics Inc
IMMU
$40M 0.42%
1,128,632
+591,558
+110% +$17.3M
APLS
50
DELISTED
Apellis Pharmaceuticals
APLS
$39.5M 0.42%
1,210,398
+818,198
+209% +$26.3M
1
2
3 4 5

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2020 Portfolio in Review

As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.

  • Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
  • Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
  • Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
  • Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
  • Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
  • Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.